The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
Switzerland’s pharmaceutical association interpharma has raised significant concerns over the potential impact of new tariffs imposed by the United States on pharmaceutical products. According to a statement from a leading Swiss industry body, these tariffs threaten to disrupt global production and supply chains, which could have far-reaching consequences for patients worldwide. The industry group has warned that the additional costs and logistical challenges introduced by these tariffs could hinder the availability of essential medicines, delay innovation, and ultimately harm patients who rely on timely access to life-saving treatments.
The tariffs, which are part of broader trade measures, are seen as a direct threat to the pharmaceutical sector’s ability to maintain efficient and cost-effective operations. Switzerland, home to some of the world’s largest pharmaceutical companies, plays a critical role in the global healthcare ecosystem. The country is a hub for research and development, as well as a key exporter of high-quality medicines. Industry representatives argue that the tariffs could undermine these strengths by increasing production costs and creating barriers to international collaboration.
One of the most pressing concerns is the potential impact on research and development. The pharmaceutical industry is heavily reliant on global networks to drive innovation, with companies often collaborating across borders to develop new treatments. The added financial burden of tariffs could force companies to scale back their R&D efforts, slowing the pace of medical advancements. This, in turn, could delay the introduction of new therapies for diseases that currently lack effective treatments.
The Swiss industry body has also highlighted the risk of supply chain disruptions. Pharmaceuticals often require complex manufacturing processes that involve multiple countries. Tariffs could complicate these processes, leading to delays and increased costs that may ultimately be passed on to patients. For individuals who depend on regular access to medications, even minor disruptions can have serious health consequences.
In light of these challenges, the Swiss pharmaceutical sector is urging policymakers to reconsider the tariffs and prioritise the needs of patients. The industry emphasises that international cooperation is essential to ensuring the continued availability of high-quality medicines and fostering innovation. Without such collaboration, the global healthcare system risks becoming fragmented, to the detriment of patients around the world.
